PLx Pharma Winddown (PLx Pharma Winddown) Valuation Rank

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PLx Pharma Winddown Valuation Rank Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

Executives

Rita M O'connor	officer: Chief Financial Officer	4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano	director, officer: Chief Executive Officer	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino	director, officer: Executive Chairman	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden	director	1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh	director	C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc	10 percent owner	1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman	officer: Chief Operating Officer	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden	officer: Acting Chief Financial Officer	2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381